EVNIN LUKE 4

4 · Werewolf Therapeutics, Inc. · Filed May 13, 2026

AI-generated summary of this filing

Updated May 13, 2026

Werewolf Therapeutics (HOWL) Director Luke Evnin Sells 44,679 Shares

What Happened

Luke Evnin, a director of Werewolf Therapeutics, sold 44,679 shares on May 13, 2026 in open-market transactions. The sales were reported at a weighted average price of $0.54 per share for total proceeds of about $24,127. The reported per-share prices ranged from $0.5077 to $0.61. The disposition was effected pursuant to a Rule 10b5-1 trading plan.

Key Details

Transaction date: 2026-05-13; Transaction type: Sale (Code S); effected under a 10b5-1 plan dated March 26, 2026 (F1).
Shares sold: 44,679; weighted average price: $0.54; price range: $0.5077–$0.61 (multiple trades) (F3).
Proceeds: approximately $24,127.
Breakdown of which affiliated accounts sold shares: AM LLC (4,787), BV 2014 (30,223), BV 2014(B) (2,016), AM BV2014 (1,040), MPM OIF (6,613) (F2).
Reported holdings across those affiliated entities after the transaction total about 1,126,496 shares (AM LLC 120,693; BV 2014 762,031; BV 2014(B) 50,824; AM BV2014 26,227; MPM OIF 166,721) (F5).
Relationship note: Evnin is affiliated with the selling entities (member/MD/manager) and disclaims beneficial ownership except to the extent of any pecuniary interest (F4).
Filing timeliness: Reported with the same period date (2026-05-13); no late filing indicated.

Context

The sale was planned under a Rule 10b5-1 program, which typically schedules trades in advance and is considered a routine way insiders monetize holdings; such planned sales generally do not, by themselves, indicate a change in insider sentiment.

Form 4

Period: 2026-05-13

Director

Transactions

Sale
Common Stock
[F1][F2][F3][F4][F5]
2026-05-13$0.54/sh−44,679$24,127→ 1,126,496 total(indirect: See Footnotes)

Footnotes (5)

[F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated March 26, 2026.
[F2]The shares were sold as follows: 4,787 by MPM Asset Management LLC ("AM LLC"), 30,223 by MPM BioVentures 2014, L.P. ("BV 2014"), 2,016 by MPM BIoVentures 2014(B), L.P. ("BV 2014(B)"), 1,040 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 6,613 by MPM Oncology Innovations Fund, L.P. ("MPM OIF").
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5077 to $0.61 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Luke Evnin is a member of AM LLC, a Managing Director of BV LLC and a manager of MPM OIF GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
[F5]The shares are held as follows: 120,693 by AM LLC, 762,031 by BV 2014, 50,824 by BV 2014(B), 26,227 by AM BV2014 and 166,721 by MPM OIF.

Signature

/s/ Luke Evnin|2026-05-13

1 file